QUARTERLY REPORT

Second quarter 2018
QUARTERLY REPORT – 2nd QUARTER 2018

Highlights

- Radspherin® development on track to start clinical trials in Q1 2019
- New Radspherin® data presented at SNMMI
- Scientific advice meeting with NMA held
- Oncoinvent receives 12 M NOK in BIA funding

Operational Review

Radspherin® development on track to start clinical trials in Q1 2019

Advances have been made in the Radspherin® development program in the second quarter of 2018. The company has begun the upscaling of the Radspherin® production process from laboratory to pilot plant scale so that sufficient quantities of product can be manufactured for upcoming clinical trials. The Radspherin® development program is on track and clinical trials are expected be initiated in Q1 of 2019 as previously announced.

New Radspherin® data presented at SNMMI

Oncoinvent research scientist Elisa Napoli was selected to present her Radspherin® research during the Novel Radiochemistry session at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Philadelphia, USA in June. Ms. Napoli presented her findings on the release and retention of 212Pb from 224Ra-labeled microparticles. Her work shows that the release to air of 220Rn, a daughter isotope of 224Ra, appears to be significantly reduced when 224Ra is bound to microparticles and that 212Pb released through the diffusion and decay of 220Rn can be re-absorbed on the particles in suspensions.

The SNMMI Annual Meeting is a prestigious educational, scientific, research, and networking event in nuclear medicine and molecular imaging and provides physicians, technologists, pharmacists, laboratory professionals, and scientists with an in-depth view of the latest research and development in the field as well as providing insights into practical applications for the clinic. As such, the company is honored that Ms. Napoli was selected to give an oral presentation at this year’s meeting.

Scientific advice meeting with NMA held

Oncoinvent held a scientific advice meeting with the Norwegian Medicines Agency (Statens legemiddelverk) in the second quarter. The purpose of the meeting was to seek the advice of advisors at the NMA regarding the pre-clinical and clinical development of Radspherin®.
advice provided by the NMA is not binding. It is however very valuable in designing a successful clinical protocol for the phase I clinical trial and for ensuring all necessary preclinical data and reports are included in the submission of the clinical trial application to the NMA.

Oncoinvent receives 12 M NOK in BIA funding

The Norwegian Research Council Programme for User-driven Research-based Innovation (BIA) has granted Oncoinvent twelve million NOK to be paid out over a three-year period to help the company develop its lead product Radspherin®. The funding will be paid out in increments and will be based on the company successfully reaching pre-approved milestones that have been set up in the project plans. The project includes research related to development of manufacturing and control procedures for Radspherin®, additional pre-clinical studies, and the first in human study with Radspherin® in the treatment of peritoneal carcinomatosis in ovarian cancer patients.

Financial review

Profit and loss statement

Income in the 2nd quarter of 2018 was NOK 2 369 061 as grants for the research activities from the Norwegian Research Council were recognized. The support from the BIA program is included with NOK 2 000 000.

Total operating expenses were increased to NOK 8 056 856 in the 2nd quarter of 2018 from NOK 3 852 338 in the same quarter in 2017. Other operating expenses increased to NOK 5 419 130 in the 2nd quarter of 2018 compared to NOK 2 514 876 in the same quarter of 2017, mainly due to expenses associated with the manufacturing operations in the laboratory facility in Nydalen. Depreciations as included in other operational expenses amounted to NOK 956 751 in the 2nd quarter.

A broad range and high level of expertise is required for the in-house production of Radspherin at the facility in Nydalen. In order to secure the quality and quantity of Radspherin, and the approvals required for the first clinical trial to commence in 2019, payroll and related expenses increased to NOK 2 637 726 in the 2nd quarter of 2018 compared to NOK 1 337 462 in the same quarter of 2017.
Key figures

<table>
<thead>
<tr>
<th>Amounts in NOK</th>
<th>2nd quarter</th>
<th>1st half</th>
<th>Full year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other income</td>
<td>2 369 061</td>
<td>359 666</td>
<td>2 836 774</td>
</tr>
<tr>
<td>Payroll and related expenses</td>
<td>-2 637 726</td>
<td>-1 337 462</td>
<td>-6 185 026</td>
</tr>
<tr>
<td>Other operating expenses</td>
<td>-5 419 130</td>
<td>-2 514 876</td>
<td>-11 936 922</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>-8 056 856</td>
<td>-3 852 338</td>
<td>-18 121 948</td>
</tr>
<tr>
<td>Financecost and other income</td>
<td>5 969</td>
<td>-7 932</td>
<td>9 759</td>
</tr>
<tr>
<td><strong>Net operating profit (loss) for the period</strong></td>
<td>-5 681 826</td>
<td>-3 500 604</td>
<td>-15 275 415</td>
</tr>
<tr>
<td>Net proceeds from equity issue</td>
<td>25 000</td>
<td>0</td>
<td>25 000</td>
</tr>
<tr>
<td>Cash and cash equivalents, end of period</td>
<td>170 889 980</td>
<td>215 211 610</td>
<td>170 889 980</td>
</tr>
<tr>
<td>Outstanding shares, beginning of period</td>
<td>13 184 681</td>
<td>13 184 681</td>
<td>13 184 681</td>
</tr>
<tr>
<td>Outstanding shares, end of period</td>
<td>13 187 181</td>
<td>13 184 681</td>
<td>13 187 181</td>
</tr>
</tbody>
</table>

Statement of financial position

In February 2017, Onco Invent received net proceeds from the private placement at the amount of NOK 210 283 494. On Jun 30, 2018, Onco Invent had total assets of NOK 197 968 530, with cash and cash equivalents of NOK 170 889 980. Shareholders equity was NOK 195 413 022.

Oslo, 11. September 2018

The Board of Directors

Onco Invent AS

IR Contact

CEO Jan A. Alfheim, alfheim@onco inventor.com, mobile +47 464 40 045

CFO Ole Peter Nordby, nordby@onco inventor.com, mobile +47 412 87 179

Onco Invent AS, Gullhaugveien 7, 0484 Oslo, onco inventor@onco inventor.com

September 2018

Quarterly report Q2-2018
Company news and updates

Oncoinvent will on a quarterly basis present the company’s development, including financial updates, through a newsletter.

Press releases will be issued whenever Oncoinvent reaches important milestones or significant events take place at the company.

Additional Information

Glossary of Terms

**microparticles**: Microparticles are particles between 0.1 and 100 micrometers in size. Commercially available microparticles are manufactured in a wide variety of materials, including ceramics, glass, polymers, and metals. Microparticles have been found to have widespread applications in medicine, biochemistry, colloid chemistry, and aerosol research.

**peritoneal carcinomatosis**: Peritoneal carcinomatosis is a type of cancer that occurs in the peritoneum, the thin layer of tissue that covers abdominal organs and surrounds the abdominal cavity. The disease develops when cancers of the appendix, colon, ovaries or other organs spread to the peritoneum and cause tumors to grow.

**peritoneal cavity**: The space within the abdomen that contains the intestines, the stomach, and the liver. It is bound by thin membranes.

**Radspherin®**: Oncoinvent’s lead product candidate currently being developed to treat peritoneal carcinomatosis

**radioisotope**: A radioisotope (radioactive nuclide, radionuclide, or radioactive isotope) is an atom that has excess nuclear energy, making it unstable. This excess energy can be either emitted from the nucleus as gamma radiation, or create and emit from the nucleus a new particle (alpha particle or beta particle), or transfer this excess energy to one of its electrons, causing that electron to be ejected as a conversion electron. During those processes, the radionuclide is said to undergo radioactive decay.

**radiotherapeutics**: the treatment of disease, especially cancer, by means of alpha or beta particles emitted from an implanted or ingested radioisotope, or by means of a beam of high-energy radiation.